January - March
- Total revenue of
SEK 3,661 M (4,639), -21 per cent and -13 per cent at CER -
EBITA1 was
SEK 1,484 M (2,173), with an EBITA margin1 of 41 percent (47) - Earnings per share (EPS) before dilution of
SEK 2.36 (4.02) -
Haematology sales were
SEK 1,877 M (2,394), Doptelet® grew by 222 per cent at CER toSEK 180 M -
Sales for Elocta® was
SEK 857 M (1,359), for Alprolix®SEK 413 M (488), with patient growth of 6 and 16 per cent -
Immunology sales were
SEK 1,554 M (1,800), Gamifant® grew by 47 per cent at CER toSEK 133 M -
Cash flow from operating activities of
SEK 1,699 M (1,886) - Doptelet (avatrombopag) was approved in the EU for treatment of ITP
-
Kineret® (anakinra) was approved in
Russia for the treatment of CAPS
Financial outlook 2021 - unchanged
- Revenue for the full-year 2021 is expected to be in the range of
SEK 14,000-15,000 M - EBITA margin is expected to be in the range of 30--35 per cent of revenue
Significant event after the reporting period
- In May,
Sobi and Hellenic Institute for the Study of Sepsis reported that use of anakinra improved overall clinical outcomes by 64% in hospitalised patients with COVID-19 pneumonia.
"The COVID-19 pandemic, with its related restrictions and lockdowns, has continued to impact our markets and operations. I believe that we will be able to recover many of the adverse effects of COVID-19 over time. Despite this unfavourable environment we have been able to strategically progress our core portfolio. We have advanced key products, such as pegcetacoplan and efanesoctocog alfa, in our R&D portfolio, and we are exploring new opportunities for anakinra for the treatment of hyperinflammation related to COVID-19."
Financial Summary
Q1 | Q1 | Full-year | ||
Amounts in SEK M | 2021 | 2020 | Change | 2020 |
Total revenue | 3,661 | 4,639 | -21% | 15,261 |
Gross profit | 2,935 | 3,598 | -18% | 12,036 |
Gross margin1 | 80% | 78% | 79% | |
EBITA1 | 1,484 | 2,173 | -32% | 6,700 |
EBITA adjusted1,2 | 1,484 | 2,173 | -32% | 6,301 |
EBITA margin1 | 41% | 47% | 44% | |
EBITA margin adjusted1,2 | 41% | 47% | 41% | |
Profit for the period | 696 | 1,182 | -41% | 3,245 |
Earnings per share, before dilution, SEK | 2.36 | 4.02 | -41% | 11.01 |
Earnings per share, before dilution, SEK adjusted1,2,3 | 2.36 | 4.02 | -41% | 9.66 |
1Alternative Performance Measures (APMs). | ||||
2EBITA full-year 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of | ||||
3EPS full-year 2020 excluding the reversal of the CVR liability of |
Telephone conference
Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CET. The event will be hosted by Sobi's CEO and President,
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 505 583 57
US: +1 646 722 49 04
Click here to go to the live webcast.
After the live event the webcast will be available on-demand via the same link.
---
About Sobi(TM)
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across
This information is information that
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 767 248 830
maria.kruse@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-report-for-the-first-quarter-2021,c3339130
https://mb.cision.com/Main/14266/3339130/1411829.pdf
(c) 2021 Cision. All rights reserved., source